Leslie Meltzer
Chief Tech/Sci/R&D Officer en ORCHARD THERAPEUTICS PLC .
Perfil
Leslie Meltzer is currently the Chief Medical Officer at Orchard Therapeutics Plc.
Prior to this role, Dr. Meltzer served as the Vice President-Medical Affairs at Keryx Biopharmaceuticals, Inc. from 2016 to 2018.
Dr. Meltzer holds a doctorate degree from Stanford University School of Medicine.
Cargos activos de Leslie Meltzer
| Empresas | Cargo | Inicio |
|---|---|---|
| ORCHARD THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 01/06/2018 |
Antiguos cargos conocidos de Leslie Meltzer.
| Empresas | Cargo | Fin |
|---|---|---|
| KERYX BIOPHARMACEUTICALS | Chief Tech/Sci/R&D Officer | 01/06/2018 |
Formación de Leslie Meltzer.
| Stanford University School of Medicine | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Leslie Meltzer
